研究动态
Articles below are published ahead of final publication in an issue. Please cite articles in the following format: authors, (year), title, journal, DOI.

构建和验证一个与甲状腺癌预后和靶向药物反应相关的PANoptosis相关lncRNA标记。

Construction and validation of a PANoptosis-related lncRNA signature for predicting prognosis and targeted drug response in thyroid cancer.

发表日期:2023
作者: Ruowen Li, Mingjian Zhao, Min Sun, Chengxu Miao, Jinghui Lu
来源: GENES & DEVELOPMENT

摘要:

甲状腺癌(TC)是内分泌系统中最常见的恶性肿瘤。PANoptosis是一种新发现的细胞死亡途径,对肿瘤研究具有兴趣。然而,PANoptosis相关的长链非编码RNA(PRlncRNA)与TC之间的关系尚不清楚。该研究旨在基于TC中的PRlncRNA开发一个预后模型。通过Pearson相关分析、单变量/多变量Cox分析和Lasso Cox回归分析,分析了PANoptosis相关基因的基因表达数据和来自The Cancer Genome Atlas(TCGA)数据库中的TC的临床信息。构建了一个PRlncRNA签名,并用于开发一个预测总体生存(OS)的正态图。我们进一步探讨了风险评分与肿瘤免疫微环境、免疫检查点和药物敏感性之间的相关性。此外,我们验证了TC细胞系中lncRNA的表达和生物功能。最后,我们使用了七种PRlncRNA构建了一个预测TC患者OS的预后模型。我们发现风险评分与肿瘤微环境(TME)和关键免疫检查点的表达有关。此外,我们筛选出可能对高风险或低风险TC群体敏感的药物。定量实时聚合酶链反应(qRT-PCR)结果显示四种PRlncRNA(GAPLINC、IDI2-AS1、LINC02154和RBPMS-AS1)在肿瘤和正常组织间的差异表达。此外,使用GEO数据库(GSE33630)验证了PRLncRNA在THCA组织和正常组织中的表达差异。最后,发现RBPMS-AS1能抑制TC细胞的增殖和迁移。总之,我们开发了一个与PANoptosis有关的lncRNA预后风险模型,可以全面了解TC患者的TME状况,并为选择敏感药物和免疫疗法奠定基础。© 2023 李等
Thyroid cancer (TC) is the most prevalent malignancy of the endocrine system. PANoptosis, a newly discovered cell death pathway, is of interest in tumor research. However, the relationship between PANoptosis-related lncRNAs (PRlncRNAs) and TC remains unclear. The study aimed to develop a prognostic model based on PRlncRNAs in TC. Gene expression data of PANoptosis-associated genes and clinical information on TC from The Cancer Genome Atlas (TCGA) database were analyzed by Pearson correlation analysis, univariate/multivariate Cox analysis, and Lasso Cox regression analysis. A PRlncRNA signature was constructed and used to develop a nomogram to predict overall survival (OS). We further explored the correlation between the risk score and tumor immune microenvironment, immune checkpoints, and drug sensitivity. Moreover, we verified the expression and biological function of lncRNAs in TC cell lines. Finally, seven PRlncRNAs were used to construct a prognostic model for predicting the OS of TC patients. We found that the risk score was associated with the tumor microenvironment (TME) and the expression of critical immune checkpoints. In addition, we screened for drugs that high- or low-risk TC groups might be sensitive to. Quantitative real-time polymerase chain reaction (qRT-PCR) results showed differential expression of four PRlncRNAs (GAPLINC, IDI2-AS1, LINC02154, and RBPMS-AS1) between tumor and normal tissues. Besides, a GEO database (GSE33630) was used to verify the expression differences of PRLncRNAs in THCA tissues and normal tissues. Finally, RBPMS-AS1 was found to inhibit the proliferation and migration of TC cells. In conclusion, we developed a PANoptosis-related lncRNA prognostic risk model that offers a comprehensive understanding of TME status in patients with TC and establishes a foundation for the choice of sensitive medications and immunotherapy.© 2023 Li et al.